Belgium-based life sciences company Pronota has finally closed its second round of funding after nearly a year with a final total of €7.9m ($9.8m). Johnson and Johnson Development Corporation, the in-house venture capital arm of the US-based consumer and medical goods company, and MP Healthcare Venture Management, a jointly-owned subsidiary of Mitsubishi Tanabe Pharma Corp and its parent Mitsubishi Chemical, had originally backed Pronota’s series B last summer. The additional €1.5m ($1.9m) came from MedSciences Capital, the venture capital arm of Dutch merchant bank Kempen. Pronota’s other investors included Benelux-based private equity firm GIMV, Biotech Fund Flanders, Life Science Partners, KBC Private Equity, VIB and the Baekeland fund, the venture capital fund of the Ghent University Association. In August 2006, Pronota, when it was called Peakadilly, closed its series A financing at €14.5m ($18.2m), two years after the company was founded. Its series A round investors were GIMV, Life Science Partners, KBC Private Equity, Baekeland and Johnson and Johnson Development Corporation.  

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?